Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis
Article in Arthritis & Rheumatology (June 2023)
The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.
Article in Arthritis & Rheumatology (June 2023)
Article in Rheumatic Disease Clinics of North America (November 2022)
Book chapter (August 2022)